{"schema_version":"secwatch.filing_event.v1","accession":"0001157523-22-001032","form_type":"8-K","ticker":"EWTX","cik":"0001710072","company_name":"Edgewise Therapeutics, Inc.","filed_at":"2022-08-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:56.740215+00:00","generated_at":"2026-06-24T04:17:12.758516+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Edgewise reports Q2 net loss $0.32/sh; positive EDG-5506 BMD interim data","bullets":["Cash and equivalents $248.4M as of June 30; expected to fund operations through end of 2024.","Net loss $16.1M ($0.32/sh) for Q2 2022 vs $14.7M ($0.30/sh) prior quarter.","ARCH study: CK reduced 30%, TNNI2 reduced 68% after 2 months of EDG-5506 10 mg daily.","Enrolling CANYON Phase 2 trial of EDG-5506 in BMD; plan to start Phase 2 in DMD in 2022.","Preclinical EDG-002 program for HCM advancing; IND-enabling studies planned in 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001157523-22-001032","json":"https://secwatch.observer/filing/0001157523-22-001032.json","markdown":"https://secwatch.observer/filing/0001157523-22-001032.md","text":"https://secwatch.observer/filing/0001157523-22-001032.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1710072/000115752322001032/0001157523-22-001032-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1710072/000115752322001032/a52801668.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T04:17:12.758516+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}